Navigation Links
Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
Date:5/21/2008

Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials will not support approval, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of products, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
5. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
6. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
7. Napo Presents at ISPOR Meeting in Toronto
8. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
9. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015 In ... malaria and tuberculosis combined[1]. Approximately 40 percent of cancer cases ... the right treatment[3]. Together with Elekta, ministries of health in ... their radiation therapy infrastructures and save lives. More ... from radiation therapy[4] during the course of their disease, either ...
(Date:5/6/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4fgrnh/asiapacific ) ... Internal Trauma Fixation Devices Market by Type & ... report to their offering. The ... to grow at a CAGR of 6.7% from ... rising incidences of road accidents, increasing aging population, ...
(Date:5/6/2015)... GenSpera, Inc. (OTCQB: GNSZ) announced today that the patent ... process in 17 countries and regions, including Europe ... China , Brazil and ... patent application will extend the exclusivity period for GenSpera,s core ... drug candidate, mipsagargin, until 2033. This recent patent ...
Breaking Medicine Technology:Elekta to bring cancer treatment to millions in Africa 2Elekta to bring cancer treatment to millions in Africa 3Elekta to bring cancer treatment to millions in Africa 4Asia-Pacific Internal Trauma Fixation Devices (Internal Trauma Fixation Plates, Screws, Rod Wires & Pins, Fusion Nails) Market 2015 2GenSpera Enters National Phase with Patent Application for Injectable Prodrug Formulations 2
... counterparts when it comes to the consumption of mental health ... as compared to 15 percent of men.  These are findings ... MHS ) that were presented Saturday at the 2012 Women,s ... The study reviewed the pharmacy claims of more ...
... 19, 2012 Ventana Medical Systems, Inc. ( ... is now introducing a novel platform for special ...  Answering customers, challenges with their current process, the ... walk-away automation, baking through staining including deparaffinization, random ...
Cached Medicine Technology:The Mental Health Gender Gap: Women Far Exceed Men in their Use of Psychotropic Medications as Utilization Increases Among Both Sexes 2The Mental Health Gender Gap: Women Far Exceed Men in their Use of Psychotropic Medications as Utilization Increases Among Both Sexes 3Ventana Introduces the BenchMark Special Stains Platform 2Ventana Introduces the BenchMark Special Stains Platform 3
(Date:5/6/2015)... May 06, 2015 In March, Dr. ... the 8th Milano Masterclass. As Europe’s most exclusive rhinoplasty ... plastic surgeons. Dr. Batniji was hand chosen to speak ... and Reconstructive Surgery, Dr. Pietro Palma. , The ... The conference hosts a diverse, multi-national faculty; each considered ...
(Date:5/6/2015)... The 2015 STEMtech conference exhibition hall floor plan ... selection . Don’t miss this opportunity to highlight your ... decision-makers from around the country. , This year’s event ... Grand in Phoenix. This beautiful all-suite hotel is nestled ... the South Mountain Preserve. The Phoenix area offers southwestern ...
(Date:5/6/2015)... Norcross, GA (PRWEB) May 06, 2015 ... has chosen Hexagon Geospatial technology to manage and distribute ... , Australia is one of the driest continents on ... supply through times of drought and erratic seasonal rainfalls ... water supply solutions. , Water NSW manages raw water ...
(Date:5/6/2015)... The Florida Council on Compulsive Gambling, Inc. (FCCG), ... Area Geriatric Education Center, Mental Health Association of Southeast ... Substance Abuse, will hold its annual conference in Ft ... Hotel. , This important event will address topics such ... as clinical training for problem gambling treatment services. ...
(Date:5/6/2015)... Hollywood, California (PRWEB) May 06, 2015 ... Avalon Hollywood, Choices Recovery sponsored Durkin Entertainment’s “RockNRolla” ... world’s top providers of products and services that ... by Debbie Durkin, Los Angeles’ leading producer of ... EcoLuxe Lunge is a premier red carpet event ...
Breaking Medicine News(10 mins):Health News:California Surgeon Speaks at International Rhinoplasty Conference 2Health News:STEMtech Conference Exhibitors Gain Access to Community College and University Representatives From Across the U.S. 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 3Health News:Conference on Problem Gambling to be held in Ft. Lauderdale, FL 2Health News:Choices Recovery Mishawaka Discusses the Many Forms of Addiction and Treatment with Terrah Bennett Smith 2
... ... be a profitable 2010, the new Wella SP range is set to raise the ... ... hair company in the world, Wella is at the forefront of hairdressing innovation. The introduction ...
... ... struggle to find the balance between investing in the necessary internal resources to implement ... for a dozen online tactics, and identifies where companies are using each tactic in ... ...
... ... of the most common negative patterns in a relationship. Angry individuals may be aware of ... Path.com. , ... (PRWEB) February 1, 2010 -- Personal Power Path announces the launch of an anger management ...
... , Feb. 1 /PRNewswire / -- Ervin Cohen ... announced today that David Bricker , Of Counsel to ... clients last Friday, January 29, 2010 , in a medical malpractice ... Hopp of the Riverside Superior Court and a jury panel of 12. ...
... , BIRMINGHAM, Ala. , Feb. 1 ... Jon P. Stonehouse , President and Chief Executive Officer of BioCryst, plans ... forodesine and BCX4208 at the 12 th Annual BIO CEO ... at 10:30 a.m. Eastern Time . , Links to a ...
... contrast agent gadolinium during magnetic resonance imaging (MRI) for ... metastases, according to a new study published online February ... Institute . Gadolinium-enhanced MRI is primarily used to visualize ... and evaluate lymph node metastases. In light of this ...
Cached Medicine News:Health News:ckwrites.com Releases Report On Creating Online Marketing Tactics 2Health News:Prominent Beverly Hills Law Firm Awarded $16.5 Million Medical Malpractice Jury Verdict 2Health News:Prominent Beverly Hills Law Firm Awarded $16.5 Million Medical Malpractice Jury Verdict 3Health News:BioCryst To Present At 12th Annual BIO CEO & Investor Conference 2Health News:News brief: Contrast agent with MRI improves detection of lymph nodes metastases 2
The MC-3 allows for simultaneous use of two lamps, with an additional built-in spare....
Xenon technology achieves a higher efficiency than halogen light sources. Consequently they provide more light....
Delivers one primary lamp and one backup lamp. The port accepts ACMI fiberoptic cables....
A three lamp light source maximizes use by allowing two surgeons to work simultaneously from it, while the third lamp is reserved for backup....
Medicine Products: